Advanced SearchSearch Tips
Review on the Efficacy of Omega-3 in the Treatment of Attention-Deficit Hyperactivity Disorder
facebook(new window)  Pirnt(new window) E-mail(new window) Excel Download
 Title & Authors
Review on the Efficacy of Omega-3 in the Treatment of Attention-Deficit Hyperactivity Disorder
Park, So-Young; Lee, Soyoung Irene; Lee, Moon-Soo;
  PDF(new window)
Pharmacotherapy is considered the first line therapy in attention-deficit hyperactivity disorder (ADHD). Many patients also choose complementary medicine such as dietary supplements. Omega-3 has shown some efficacy for improving ADHD symptoms in several studies. The goal of this review is to integrate the previous research findings on omega-3 and understand the issues worth considering in the treatment of ADHD. The terms "attention deficit disorder with hyperactivity", "omega-3", and "dietary supplements" were searched on PubMed, Cochrane, and Google scholar. The search was further limited to clinical trials, reviews, and meta-analyses. Trials that examined treatments for ADHD, used randomized design, and placebo-controlled trials were included. Eighteen clinical trials with a total of 1,141 participants were included in this review. Fifteen trials had parallel designs, comparing an omega-3/6 polyunsaturated fatty acid (PUFAs) or a combination of both to a placebo and three compared omega-3/6 PUFAs to a placebo and psycho-stimulants. Seven of the included trials showed significant improvements in groups receiving omega-3/6 PUFAs compared to placebo groups, however, 11 trials showed no significant differences. Evidence that PUFAs supplementation provides benefits for ADHD was yet limited. Mixed results were due to selection variability criteria, variability of supplementation, and short follow-up intervals.
ADHD;Omega-3;Polyunsaturated Fatty Acids;
 Cited by
Clinical practice guideline: diagnosis and evaluation of the child with attention-deficit/hyperactivity disorder. American Academy of Pediatrics. Pediatrics 2000;105:1158-1170. crossref(new window)

Goldman LS, Genel M, Bezman RJ, Slanetz PJ. Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Council on Scientific Affairs, American Medical Association. JAMA 1998;279:1100-1107. crossref(new window)

Cho SC. Concept and biological study of attention deficit hyperactivity disorder. J Korean Acad Child Adolesc Psychiatry 1990;1:5-26.

Ahn DH, Hong KE. Management of the child with attention - deficit hyperactivity disorders (ADHD). J Korean Acad Child Adolesc Psychiatry 1990;1:77-88.

Spencer T, Biederman J, Wilens T, Harding M, O'Donnell D, Griffin S. Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle. J Am Acad Child Adolesc Psychiatry 1996;35:409-432. crossref(new window)

Yang YH, Yoo HJ. Stimulants medication of attention-deficit hyperactivity disorder. J Korean Acad Child Adolesc Psychiatry 2008;19:61-71.

Lewis M. Child and adolescent psychiatry: a comprehensive textbook. Philadelphia, PA: Lippincott Williams & Wilkins;2002.

Connor DF, Fletcher KE, Swanson JM. A meta-analysis of clonidine for symptoms of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1999;38:1551-1559. crossref(new window)

Cheng JY, Chen RY, Ko JS, Ng EM. Efficacy and safety of atomoxetine for attention-deficit/hyperactivity disorder in children and adolescents-meta-analysis and meta-regression analysis. Psychopharmacology (Berl) 2007;194:197-209. crossref(new window)

Schachter HM, Pham B, King J, Langford S, Moher D. How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents? A metaanalysis. CMAJ 2001;165:1475-1488.

Barkley RA, McMurray MB, Edelbrock CS, Robbins K. Side effects of methylphenidate in children with attention deficit hyperactivity disorder: a systemic, placebo-controlled evaluation. Pediatrics 1990;86:184-192.

Swanson JM, Kraemer HC, Hinshaw SP, Arnold LE, Conners CK, Abikoff HB, et al. Clinical relevance of the primary findings of the MTA: success rates based on severity of ADHD and ODD symptoms at the end of treatment. J Am Acad Child Adolesc Psychiatry 2001;40:168-179. crossref(new window)

Yoo HJ, Yang SJ, Shin D, Kang H, Kim BN, Kim JH, et al. The Korean practice parameter for the treatment of attention-deficit hyperactivity disorder(III): pharmacologic treatment. J Korean Acad Child Adolesc Psychiatry 2007;18:16-25.

Conners CK, Epstein JN, March JS, Angold A, Wells KC, Klaric J, et al. Multimodal treatment of ADHD in the MTA: an alternative outcome analysis. J Am Acad Child Adolesc Psychiatry 2001;40:159-167. crossref(new window)

Berger I, Dor T, Nevo Y, Goldzweig G. Attitudes toward attentiondeficit hyperactivity disorder (ADHD) treatment: parents' and children's perspectives. J Child Neurol 2008;23:1036-1042. crossref(new window)

Dunnick JK, Hailey JR. Experimental studies on the long-term effects of methylphenidate hydrochloride. Toxicology 1995;103:77-84. crossref(new window)

Pelham WE Jr, Waschbusch DA. Behavioral intervention in attention- deficit/hyperacivity disorder. In: Quay HC, Hogan AE, editors. Handbook of disruptive behavior disorders. New York: Springer; 1999. p.255-278.

Kim BN, Yoo HK, Kang H, Kim JH, Shin D, Ahn D, et al. The Korean practice parameter for the treatment of attention-deficit hyperactivity disorder (IV): non-pharmacologic treatment. J Korean Acad Child Adolesc Psychiatry 2007;18:26-30.

Safren SA, Sprich S, Mimiaga MJ, Surman C, Knouse L, Groves M, et al. Cognitive behavioral therapy vs relaxation with educational support for medication-treated adults with ADHD and persistent symptoms: a randomized controlled trial. JAMA 2010;304:875-880. crossref(new window)

Pelham WE Jr, Wheeler T, Chronis A. Empirically supported psychosocial treatments for attention deficit hyperactivity disorder. J Clin Child Psychol 1998;27:190-205. crossref(new window)

Barkley RA, DuPaul GJ, McMurray MB. Comprehensive evaluation of attention deficit disorder with and without hyperactivity as defined by research criteria. J Consult Clin Psychol 1990;58:775-789. crossref(new window)

Bourre JM. Effects of nutrients (in food) on the structure and function of the nervous system: update on dietary requirements for brain. Part 1: micronutrients. J Nutr Health Aging 2006;10:377-385.

Fernstrom JD. Can nutrient supplements modify brain f unction? Am J Clin Nutr 2000;71(6 Suppl):1669S-1675S. crossref(new window)

Sarris J, Kean J, Schweitzer I, Lake J. Complementary medicines (herbal and nutritional products) in the treatment of attention deficit hyperactivity disorder (ADHD): a systematic review of the evidence. Complement Ther Med 2011;19:216-227. crossref(new window)

Arnold LE, Hurt E, Lofthouse N. Attention-deficit/hyperactivity disorder: dietary and nutritional treatments. Child Adolesc Psychiatr Clin N Am 2013;22:381-402, v. crossref(new window)

Rucklidge JJ, Johnstone J, Kaplan BJ. Nutrient supplementation approaches in the treatment of ADHD. Expert Rev Neurother 2009;9:461-476. crossref(new window)

Sinn N, Bryan J. Effect of supplementation with polyunsaturated fatty acids and micronutrients on learning and behavior problems associated with child ADHD. J Dev Behav Pediatr 2007;28:82-91. crossref(new window)

Gustafsson PA, Birberg-Thornberg U, Duchén K, Landgren M, Malmberg K, Pelling H, et al. EPA supplementation improves teacher-rated behaviour and oppositional symptoms in children with ADHD. Acta Paediatr 2010;99:1540-1549. crossref(new window)

Perera H, Jeewandara KC, Seneviratne S, Guruge C. Combined ${\omega}3$ and ${\omega}6$ supplementation in children with attention-deficit hyperactivity disorder (ADHD) refractory to methylphenidate treatment: a double- blind, placebo-controlled study. J Child Neurol 2012;27:747-753. crossref(new window)

Yehuda S, Rabinovitz-Shenkar S, Carasso RL. Effects of essential fatty acids in iron deficient and sleep-disturbed attention deficit hyperactivity disorder (ADHD) children. Eur J Clin Nutr 2011;65:1167-1169. crossref(new window)

Richardson AJ, Puri BK. A randomized double-blind, placebo-controlled study of the effects of supplementation with highly unsaturated fatty acids on ADHD-related symptoms in children with specific learning difficulties. Prog Neuropsychopharmacol Biol Psychiatry 2002;26:233-239. crossref(new window)

Vaisman N, Kaysar N, Zaruk-Adasha Y, Pelled D, Brichon G, Zwingelstein G, et al. Correlation between changes in blood fatty acid composition and visual sustained attention performance in children with inattention: effect of dietary n-3 fatty acids containing phospholipids. Am J Clin Nutr 2008;87:1170-1180. crossref(new window)

Manor I, Magen A, Keidar D, Rosen S, Tasker H, Cohen T, et al. The effect of phosphatidylserine containing omega3 fatty-acids on attention-deficit hyperactivity disorder symptoms in children: a double-blind placebo-controlled trial, followed by an open-label extension. Eur Psychiatry 2012;27:335-342. crossref(new window)

Milte CM, Parletta N, Buckley JD, Coates AM, Young RM, Howe PR. Eicosapentaenoic and docosahexaenoic acids, cognition, and behavior in children with attention-deficit/hyperactivity disorder: a randomized controlled trial. Nutrition 2012;28:670-677. crossref(new window)

Stevens L, Zhang W, Peck L, Kuczek T, Grevstad N, Mahon A, et al. EFA supplementation in children with inattention, hyperactivity, and other disruptive behaviors. Lipids 2003;38:1007-1021. crossref(new window)

Raz R, Carasso RL, Yehuda S. The influence of short-chain essential fatty acids on children with attention-deficit/hyperactivity disorder: a double-blind placebo-controlled study. J Child Adolesc Psychopharmacol 2009;19:167-177. crossref(new window)

Voigt RG, Llorente AM, Jensen CL, Fraley JK, Berretta MC, Heird WC. A randomized, double-blind, placebo-controlled trial of docosahexaenoic acid supplementation in children with attention-deficit/hyperactivity disorder. J Pediatr 2001;139:189-196. crossref(new window)

Johnson M, Ostlund S, Fransson G, Kadesjö B, Gillberg C. Omega-3/omega-6 fatty acids for attention deficit hyperactivity disorder: a randomized placebo-controlled trial in children and adolescents. J Atten Disord 2009;12:394-401. crossref(new window)

Bélanger SA, Vanasse M, Spahis S, Sylvestre MP, Lippe S, L'heureux F, et al. Omega-3 fatty acid treatment of children with attention-deficit hyperactivity disorder: a randomized, double-blind, placebo-controlled study. Paediatr Child Health 2009;14:89-98. crossref(new window)

Aman MG, Mitchell EA, Turbott SH. The effects of essential fatty acid supplementation by Efamol in hyperactive children. J Abnorm Child Psychol 1987;15:75-90. crossref(new window)

Arnold LE, Kleykamp D, Votolato NA, Taylor WA, Kontras SB, Tobin K. Gamma-linolenic acid for attention-deficit hyperactivity disorder: placebo-controlled comparison to D-amphetamine. Biol Psychiatry 1989;25:222-228. crossref(new window)

Hirayama S, Hamazaki T, Terasawa K. Effect of docosahexaenoic acid-containing food administration on symptoms of attention-deficit/hyperactivity disorder - a placebo-controlled double-blind study. Eur J Clin Nutr 2004;58:467-473. crossref(new window)

Raz R, Gabis L. Essential fatty acids and attention-deficit-hyperactivity disorder: a systematic review. Dev Med Child Neurol 2009; 51:580-592. crossref(new window)

Hawkey E, Nigg JT. Omega-3 fatty acid and ADHD: blood level analysis and meta-analytic extension of supplementation trials. Clin Psychol Rev 2014;34:496-505. crossref(new window)

Simopoulos AP. Omega-3 fatty acids in health and disease and in growth and development. Am J Clin Nutr 1991;54:438-463. crossref(new window)

Simopoulos AP. Omega-3 fatty acids in inflammation and autoimmune diseases. J Am Coll Nutr 2002;21:495-505. crossref(new window)

Stevens LJ, Zentall SS, Deck JL, Abate ML, Watkins BA, Lipp SR, et al. Essential fatty acid metabolism in boys with attention-deficit hyperactivity disorder. Am J Clin Nutr 1995;62:761-768. crossref(new window)

Antalis CJ, Stevens LJ, Campbell M, Pazdro R, Ericson K, Burgess JR. Omega-3 fatty acid status in attention-deficit/hyperactivity disorder. Prostaglandins Leukot Essent Fatty Acids 2006;75:299-308. crossref(new window)

Joshi K, Lad S, Kale M, Patwardhan B, Mahadik SP, Patni B, et al. Supplementation with flax oil and vitamin C improves the outcome of attention deficit hyperactivity disorder (ADHD). Prostaglandins Leukot Essent Fatty Acids 2006;74:17-21. crossref(new window)

Chalon S. Omega-3 fatty acids and monoamine neurotransmission. Prostaglandins Leukot Essent Fatty Acids 2006;75:259-269. crossref(new window)

Drane DL, Logemann JA. A critical evaluation of the evidence on the association between type of infant feeding and cognitive development. Paediatr Perinat Epidemiol 2000;14:349-356. crossref(new window)

Belfort MB, Rifas-Shiman SL, Kleinman KP, Guthrie LB, Bellinger DC, Taveras EM, et al. Infant feeding and childhood cognition at ages 3 and 7 years: effects of breastfeeding duration and exclusivity. JAMA Pediatr 2013;167:836-844. crossref(new window)

Arnold LE, Kleykamp D, Votolato N, Gibson RA, Horrocks L. Potential link between dietary intake of fatty acids and behavior: pilot exploration of serum lipids in attention-deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 1994;4:171-182. crossref(new window)

Brue AW, Oakland TD, Evans RA. The use of a dietary supplement combination and an essential fatty acid as an alternative and complementary treatment for children with attention-deficit/hyperactivity disorder. Sci Rev Altern Med 2001;5:187-194.